Table 1.
Characteristics of the whole study population and patients included and excluded from analysis.
| mITT population | Population with CEA and ctDNA | Population without CEA and/or ctDNA | ||||
|---|---|---|---|---|---|---|
| N = 2010 | n = 405 | n = 1605 | ||||
| n | % | n | % | n | % | |
| Age, years | ||||||
| Mean (SD) | 63.9 (9.4) | 62.5 (9.9) | 64.3 (9.2) | |||
| Median (Q1-Q3) | 64.7 (58.1-70.8) | 63.5 (56.4-69.6) | 65.2 (58.5-71.1) | |||
| ≤70 | 1443 | 71.8 | 310 | 76.5 | 1133 | 70.6 |
| >70 | 567 | 28.2 | 95 | 23.5 | 472 | 29.4 |
| Sex | ||||||
| Male | 1144 | 56.9 | 218 | 53.8 | 926 | 57.7 |
| Female | 866 | 43.1 | 187 | 46.2 | 679 | 42.3 |
| ECOG PS | ||||||
| 0 | 1479 | 73.6 | 325 | 80.3 | 1154 | 71.9 |
| 1-2 | 531 | 26.4 | 80 | 19.7 | 451 | 28.1 |
| Tumor and node stage | ||||||
| T1-3 and N1 | 1246 | 62.0 | 249 | 61.5 | 997 | 62.2 |
| T4 and/or N2 | 764 | 38.0 | 156 | 38.5 | 608 | 37.8 |
| Chemotherapy duration | ||||||
| 3 months | 1002 | 49.9 | 202 | 49.9 | 800 | 49.8 |
| FOLFOX | 895 | 89.3 | 178 | 88.1 | 717 | 89.6 |
| CAPOX | 107 | 10.7 | 24 | 11.9 | 83 | 10.4 |
| 6 months | 1008 | 50.1 | 203 | 50.1 | 805 | 50.2 |
| FOLFOX | 914 | 90.7 | 181 | 89.2 | 733 | 91.1 |
| CAPOX | 94 | 9.3 | 22 | 10.8 | 72 | 8.9 |
| Primary tumor site | ||||||
| Left | 1161 | 60.4 | 251 | 62.3 | 910 | 59.8 |
| Right | 746 | 38.8 | 148 | 36.7 | 598 | 39.4 |
| Both | 16 | 0.8 | 4 | 1.0 | 12 | 0.8 |
| Missing | 87 | — | 2 | — | 85 | — |
| Histologic grade | ||||||
| Low grade | 1764 | 91.7 | 345 | 89.4 | 1419 | 92.3 |
| High grade | 159 | 8.3 | 41 | 10.6 | 118 | 7.7 |
| Missing | 87 | — | 19 | — | 68 | — |
Abbreviations: mIIT, modified intent-to-treat population; CEA, carcinoembryonic antigen; ctDNA, circulating DNA; ECOG PS, Eastern Cooperative Oncology Group Performance Status.